Key result
Continuation of propranolol through coronary bypass surgery significantly reduced the incidence of subendocardial myocardial infarction (3.3% vs 20.0%, p<0.05) compared to discontinuation.
Why the study?
Does continuation of propranolol through coronary bypass surgery reduce perioperative myocardial infarction and supraventricular tachycardias in patients undergoing coronary bypass surgery?
Population
80 patients undergoing coronary bypass surgery
Comparison
Continuation of propranolol up to 4 to 10 hours… vs Discontinuation of propranolol 24 hours before…
Design
Cohort
Follow-up
up to 2 weeks postoperatively
Authors
Loading...
May reduce perioperative subendocardial MI if continued; leaves open need for modern RCTs before changing practice.
Cohort (n=80)
Does continuation of propranolol through coronary bypass surgery reduce perioperative myocardial infarction and supraventricular tachycardias in patients undergoing coronary bypass surgery?
Absolute Event Rate: 3.3% vs 20%
p-value: p=<0.05
Continuation of propranolol through coronary bypass surgery is safe and significantly reduces the incidence of perioperative subendocardial myocardial infarction and supraventricular tachycardias.
Boudoulas et al. (1979) conducted a cohort in Coronary bypass surgery (n=80). Continuation of propranolol vs. Discontinuation of propranolol 24 h before surgery was evaluated on Incidence of subendocardial myocardial infarction (p=<0.05). Continuation of propranolol through coronary bypass surgery significantly reduced the incidence of subendocardial myocardial infarction (3.3% vs 20.0%, p<0.05) compared to discontinuation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: